LOCALLY ACTING VASCULOPROTECTIVE ANTITHROMBOTICS
Aplagon is developing APACs, biological mimetics of heparin proteoglycans, as potent, first-in-class antithrombotic and vasculoprotective products for the clinical management of vascular injury related thrombotic blood vessel occlusions leading to organ damage. The initial clinical target indications include hemodialysis access failure, COVID-19/sepsis-induced coagulopathy and peripheral arterial disease, where there is significant unmet medical need.
APAC MULTIPLE MECHANISMS OF ACTION
APACs have a number of important and unique properties. The compounds are named after their unique dual antiplatelet (AP) and anticoagulant (AC) activity. They uniquely target vascular injury sites where they provide local long-term antithrombotic and anti-inflammatory action without a prolonged systemic effect. Among other benefits, this profile is anticipated to lead to a reduced bleeding risk compared with systemically acting antithrombotics.
Aplagon was established to translate proprietary scientific discoveries on APACs from bench to bedside. The Company is supported by an experienced management team and Board, an excellent scientific network, and backed by a strong syndicate of leading Finnish investors.